Overview
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.
Indication
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties. It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids. Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments. Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days). A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.
Associated Conditions
- Acute Migraine
- Eye Pain
- Inflammation
- Macular Edema, Cystoid
- Ocular Itching
- Pericarditis Acute
- Pseudophakic Cystoid Macular Oedema
- Severe Acute Pain
- Acute, moderate Pain
- Chronic aphakic cystoid macular edema
- Intraoperative miosis
- Postoperative ocular pain
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/01/06 | Phase 2 | Completed | |||
2021/11/24 | Not Applicable | UNKNOWN | |||
2021/11/01 | Phase 3 | Completed | |||
2021/10/28 | Not Applicable | Completed | Alfarabi Colleges | ||
2021/10/12 | Phase 4 | Completed | |||
2021/09/30 | Phase 1 | Completed | St. Mary's Research Center, Canada | ||
2021/09/23 | Phase 1 | Recruiting | Medstar Health Research Institute | ||
2021/06/25 | Phase 2 | Withdrawn | |||
2021/05/20 | Phase 4 | Withdrawn | Michael Khazzam | ||
2021/05/04 | Phase 3 | UNKNOWN |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| A-S Medication Solutions | 50090-6265 | ORAL | 10 mg in 1 1 | 3/15/2023 | |
| Almaject, Inc. | 72611-719 | INTRAVENOUS, INTRAMUSCULAR | 15 mg in 1 mL | 1/15/2017 | |
| Nephron SC Inc. | 0487-6232 | INTRAMUSCULAR | 30 mg in 1 mL | 10/28/2021 | |
| Camber Pharmaceuticals, Inc. | 31722-305 | INTRAVENOUS, INTRAMUSCULAR | 15 mg in 1 mL | 7/4/2023 | |
| GLENMARK PHARMACEUTICALS INC., USA | 68462-756 | INTRAMUSCULAR, INTRAVENOUS | 30 mg in 1 mL | 12/22/2023 | |
| Prasco Laboratories | 66993-193 | NASAL | 15.75 mg in 1 1 | 12/4/2023 | |
| NuCare Pharmaceuticals, Inc. | 68071-3880 | OPHTHALMIC | 5 mg in 1 mL | 7/31/2025 | |
| Direct Rx | 72189-335 | OPHTHALMIC | 5 mg in 1 mL | 3/7/2022 | |
| Terrain Pharmaceuticals | 53225-3655 | INTRAVENOUS, INTRAMUSCULAR | 15 mg in 1 mL | 12/17/2019 | |
| Eugia US LLC | 55150-340 | INTRAMUSCULAR, INTRAVENOUS | 30 mg in 1 mL | 5/18/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.